The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InReflecting the resilience of the mid-cap sector, several US companies reported record Q2 2026 results and raised their full-year financial guidance. Align Technology achieved record revenue of $1.06 billion, a 4.3% increase, while Adaptive Biotechnologies boosted its revenue outlook following growth in its diagnostic business. Additionally, FormFactor delivered record results fueled by high demand for semiconductor testing within data centers and AI infrastructure.
Per market data, these instruments showed varied performance at the close of July 28, 2026, with Align Technology (ALGN) finishing at $175.6 and FormFactor (FORM) at $88.23. Other firms in the cluster also maintained steady levels, as Adaptive Biotechnologies (ADPT) closed at $22.52 and Corcept Therapeutics (CORT) reached $94.19, signaling investor confidence in specialized tech and healthcare growth segments.
This momentum arrives as traders monitor broader macroeconomic indicators that could influence risk appetite for mid-cap equities. Based on closing prices on July 28, 2026, Alkami Technology (ALKT) stands at $18.17 and PC Connection (CNXN) at $83.1. With no immediate specific catalysts in the upcoming calendar for these firms, the market focus remains on the sustainability of AI-driven demand and data center infrastructure as primary growth drivers.